Optimal duration of additional therapy after favorable response to lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomised trial

被引：0
|
作者：
Enomoto, Masaru [1 ]
Tamori, Akihiro [1 ]
Toyama, Madoka [1 ]
Hayashi, Kohmoto Takehiro [1 ]
Morikawa, Hiroyasu [1 ]
Jomura, Hisato [1 ]
Habu, Daiki [1 ]
Sakaguchi, Hiroki [1 ]
Takeda, Tadashi [1 ]
Shiomi, Susumu [2 ]
Nishiguchi, Shuhei [3 ]
Kawada, Norifumi [1 ]
机构：
[1] Osaka City Univ, Sch Med, Dept Hepatol, Osaka, Japan
[2] Osaka City Univ, Sch Med, Dept Nucl Med, Osaka, Japan
[3] Hyogo Med Univ, Dept Internal Med, Osaka, Japan
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2007年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A250 / A250
页数：1
相关论文
共 50 条
  • [31] Biochemical response to lamivudine treatment in HBeAg negative chronic hepatitis B patients in Iran
    Alizadeh, Amir Houshang Mohammad
    Ranjbar, Mitra
    Karimi, Babak
    Hatami, Saeed
    WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (26) : 4203 - 4205
  • [32] The main reasons for finite Nuc therapy in HBeAg-negative chronic hepatitis B patients
    Chien-Wei Peng
    Wen-Juei Jeng
    Hepatology International, 2021, 15 : 527 - 528
  • [33] Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B
    Vassiliadis, Themistoklis
    Tziomalos, Konstantinos
    Patsiaoura, Kalliopi
    Zagris, Thomas
    Giouleme, Olga
    Soufleris, Konstantinos
    Grammatikos, Nikolaos
    Theodoropoulos, Konstantinos
    Mpoumponaris, Alexandros
    Dona, Konstantina
    Zezos, Petros
    Nikolaidis, Nikolaos
    Orfanou-Koumerkeridou, Eleni
    Balaska, Aikaterini
    Eugenidis, Nikolaos
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 (10) : 1582 - 1588
  • [34] Additional Measures After Stopping Nucleoside Analogues in HbeAg-Negative Chronic Hepatitis B: Better But Not Enough
    Lim, Seng gee
    Tan, Yong chuan
    GASTROENTEROLOGY, 2024, 166 (01) : 23 - 24
  • [35] Lamivudine treatment in Chinese patients with HBeAg negative chronic hepatitis B: Indefinite vs finite duration of therapy.
    Fung, SK
    Wong, F
    Hussain, MT
    Lok, AS
    HEPATOLOGY, 2001, 34 (04) : 325A - 325A
  • [36] Entecavir versus lamivudine for patients with HBeAg-Negative chronic hepatitis B (vol 354, pg 1011, 2006)
    Lai, CL
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (17): : 1863 - 1863
  • [37] Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B
    Buti, M
    Casado, MA
    Calleja, JL
    Salmerón, J
    Aguilar, J
    Rueda, M
    Esteban, R
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (03) : 409 - 419
  • [38] Treatment withdrawal after two years of lamivudine therapy in Chinese patients with HBeAg negative chronic hepatitis B
    Fung, S
    Wong, F
    Hussain, M
    Lok, AS
    HEPATOLOGY, 2002, 36 (04) : 637A - 637A
  • [39] Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis
    Chen, Y. C.
    Peng, C. Y.
    Jeng, W. J.
    Chien, R. N.
    Liaw, Y. F.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (10) : 1182 - 1191
  • [40] Short-term entecavir versus lamivudine therapy for HBeAg-negative patients with acute-on-chronic hepatitis B liver failure
    Jing Lai
    Ying Yan
    Li Mai
    Yu-Bao Zheng
    Wei-Qiang Gan
    Wei-Min Ke
    Hepatobiliary&PancreaticDiseasesInternational, 2013, 12 (02) : 154 - 159
12345